Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes.

Abstract

Allogeneic SCT is the most effective method to achieve cure in patients with MPD and MDS. This approach is associated with significant risk of morbidity (eg, GVHD) and TRM, although the incidence and severity vary based on donor and recipient characteristics. For young patients with HLA-matched donors, SCT is the preferred therapy. Efforts to improve outcome for older patients and for patients with alternative donors have led to decreased treatment-associated complications with associated better long-term DFS.

• Authors: Alan S Wayne, A J Barrett
• Journal: Hematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 17 Issue 5 Pg. 1243-60 (Oct 2003) ISSN: 0889-8588 [Print] United States
• PMID: 14560785 (Publication Type: Journal Article, Review)

Topics

• Humans
• Myelodysplastic Syndromes (therapy)
• Myeloproliferative Disorders (therapy)
• Stem Cell Transplantation
• Tissue Donors
• Transplantation, Homologous